BioSpace News Archive

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 45,040 restricted stock units of Atara’s common stock to nine newly hired employees and stock options to purchase an aggregate of 39,978 shares of Atara’s common stock to three such newly hired employees.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced that on February 28, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 15,200 shares of TCR2’s common stock to 3 new non-executive employees.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Pardes Biosciences, Inc. announced the granting of an inducement award under the Pardes’ 2022 Inducement Plan on March 2, 2022 to its new Chief Executive Officer, Thomas G. Wiggans.

Increasing investments by public and private organizations to develop advanced femtech devices, rising penetration of internet and smartphones and increasing health problems in pregnant women are key some key factors expected to drive global market revenue growth

Increasing demand for personalized medicines, improving healthcare and research infrastructure, and rising awareness about cell culture based products are some key factors expected to drive market revenue growth.

Rising prevalence of pulmonary valvular heart diseases, increasing geriatric population and increasing healthcare expenditure are some key factors expected to drive global market revenue growth.

Chromatography is a method for separating the components or solutes of a mixture and is used in various application areas including biotechnology, pharmaceutical, food production, genetic engineering, and drug discovery among many others.

The growth of the medical radiation detection market is attributed to surge in R&D related to medical radiation detection and increase in incidences for cancer and other diseases that require nuclear medicine for management of disease.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market.